Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Experimental Drug Blocks Growth of Virus-Induced Cancer

By BiotechDaily International staff writers
Posted on 29 Jan 2014
Image: Micrograph of KSHV-induced tumor showing abundant small branching blood vessels and spindle cells (Photo courtesy of Wikimedia Commons).
Image: Micrograph of KSHV-induced tumor showing abundant small branching blood vessels and spindle cells (Photo courtesy of Wikimedia Commons).
An experimental drug that selectively targets the enzyme sphingosine kinase (SK) blocked the growth of primary effusion lymphoma (PEL), a deadly tumor linked to the Kaposi's sarcoma-associated herpesvirus (KSHV) that frequently occurs in those infected with HIV.

Sphingosine (2-amino-4-octadecene-1,3-diol) is an 18-carbon amino alcohol with an unsaturated hydrocarbon chain, which forms a primary part of sphingolipids, a class of cell membrane lipids that include sphingomyelin, an important phospholipid.

Sphingosine can be phosphorylated in vivo via two kinases, sphingosine kinase type 1 and sphingosine kinase type 2. Phosphorylation leads to the formation of sphingosine-1-phosphate, a potent signaling lipid. Sphingolipid metabolites, such as ceramide, sphingosine, and sphingosine-1-phosphate, are lipid-signaling molecules involved in diverse cellular processes.

Sphingosine kinase catalyzes the phosphorylation of sphingosine to form sphingosine-1-phosphate (S1P), a lipid mediator with both intra- and extra-cellular functions. Intracellularly, S1P regulates proliferation and survival, and extracellularly, it is a ligand for cell surface G protein-coupled receptors. This protein, and its product S1P, play a key role in TNF-alpha signaling and the NF-kappa-B activation pathway important in inflammatory, antiapoptotic, and immune processes.

Investigators at the Louisiana State University Health Sciences Center (New Orleans, USA) and the Tulane University School of Medicine (New Orleans, LA, USA) had previously shown that the experimental SK inhibitor ABC294640, an orally available small molecule developed by Apogee Biotechnology Corporation (Hummelstown, PA, USA), induced apoptosis and blocked proliferation in a triple-negative breast cancer system. Furthermore, SK expression promoted survival and endocrine therapy resistance in previously sensitive breast cancer cells.

In the current study, which was published in the January 2014 issue of the journal Molecular Cancer Therapeutics, the investigators reported that ABC294640 induced dose-dependent caspase cleavage and apoptosis for cultured PEL cells from KSHV+ patients, in part through inhibition of constitutive signal transduction associated with PEL cell proliferation and survival. Furthermore, they demonstrated that systemic administration of ABC294640 induced tumor regression in an established human PEL xenograft model.

"It is still early in our understanding of how these special lipids contribute to viral cancers, but this is a major potential advance. There are no therapies available to fight viral tumors by selectively blocking these pathways, all while not harming normal, uninfected cells," said senior author Dr. Christopher Parsons, associate professor of medicine, microbiology, immunology, and parasitology at Louisiana State University Health Sciences Center. "Our research thus far indicates that this molecule is safe, with the potential to stand alone as a single, orally administered drug with no need to combine it with other toxic drugs now routinely used but which fail to work for many patients."

Related Links:

Louisiana State University Health Sciences Center
Tulane University School of Medicine
Apogee Biotechnology Corporation



Channels

Genomics/Proteomics

view channel
Image: Transmission electron micrograph of norovirus particles in feces (Photo courtesy of Wikimedia Commons).

Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.